Biowaste Management During Biopharmaceutical Plant Start-Up: From Regulatory Guidance to Verified Inactivation Methods - - BioPharm International

ADVERTISEMENT

Biowaste Management During Biopharmaceutical Plant Start-Up: From Regulatory Guidance to Verified Inactivation Methods


BioPharm International


Had pertinent data relating to chemical inactivation of CHO cells been available at the start-up of our facility, it would have been possible to move quickly and directly to an annual verification of the chosen methods. This paper should supply to other groups valuable in-formation that may be used in justifying the selection and use of similar inactivation procedures in their own facilities.

Mary Heenan, senior scientist, Process Development, Development & Technical Services, The Wyeth BioPharma Campus at Grange Castle, Wyeth Medica Ireland, Grange Castle International Business Park, Clondalkin Dublin 22, Ireland, 01.4696814, Fax: 01.4696896,

REFERENCES

1. Fink R, Moran E. Biosafety for large-scale containment level 1 operations using recombinant DNA technology: No emerging hazards. Applied Biosafety. 2005; 10:30-39.

2. Ebling MJ, Miller S. Validation of a batch type biological waste treatment system. Pharmaceutical Engineering. 1991;11:42-48.

3. Carlson CJ. Biowaste Systems. Pharmaceutical Engineering. 2001;21:70-82.

4. Gregoriades N, Luzardo M, Lucquet B, Ryll T. Heat inactivation of mammalian cell cultures for biowaste kill system design. Biotechnol. Prog. 2003;19:14-20.

5. Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines
Source: BioPharm International,
Click here